Comparative effect of an immunomodulator Immunoxel (DzhereloT) when used alone or in combination with antiretroviral therapy in drug-naive HIV-infected individuals
Immunomodulating agent Immunoxel (Dzherelo) has been evaluated in 70 HIV-positive individuals divided into three arms: first, control arm, received standard antiretroviral therapy zidovudine/lamivudine/efavirenz (AZT7/3TC/EFV); second-AZT/3TC/EFV+Immunoxel and third, Immunoxel alone, given orally, twice daily. At 32 weeks of follow-up CD4 cell counts increased in all arms, reaching + 102, +190 and +175 cells/mm, respectively. The proportion of patients who experienced adverse events attributable to study medication was 65%, 24% and 5%. Immunoxel attenuated hepatic toxicity in patients receiving ART as determined by liver function test. Baseline values for ALT aminotransferase were 36, 62 and 72 U/L, which at study conclusion have risen to 78 U/L in arm A, but declined to 38 and 31 U/L in arms B and C. Immunoxel also reversed AIDS-associated wasting. The average weight gain was 1.4, 6.9 and 5.1kg. The results indicate that Immunoxel is safe and exerts beneficial effect in AIDS patients.
Keywords: cachexia, hepatotoxicity, immune tolerance, CD4 cell counts, immunotherapy, phytotherapy, transaminase, antiretroviral therapy, HIV infection, immunomodulating agents, AIDS
Most popular related searches
No comments were found for Comparative effect of an immunomodulator Immunoxel (DzhereloT) when used alone or in combination with antiretroviral therapy in drug-naive HIV-infected individuals. Be the first to comment!